Key information

🔎 Fund Overview

FibroBiologics, Inc. is a cell therapy regenerative medicine company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The Company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat Multiple sclerosis (MS) and has completed the Phase I study. The Company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing.